The European Commission (EC) has granted Moderna’s COVID-19 vaccine a conditional marketing authorisation for adults.
The vaccine demonstrated a ninety-four-point-one per cent efficacy rate in reducing the number of symptomatic cases of COVID-19, during a Phase III study, in people who were given the vaccine compared to those who were given a placebo. Also, the trial showed a ninety-point-nine per cent efficacy rate in patients who were at risk of developing severe COVID-19 infection.
“The EC grants Moderna’s COVID-19 vaccine a conditional marketing authorisation for adults.“
Executive Director of EMA, Emer Cooke, stated: “This vaccine provides us with another tool to overcome the current emergency. It is a testament to the efforts and commitment of all involved that we have this second positive vaccine recommendation just short of a year since the pandemic was declared by WHO. As for all medicines, we will closely monitor data on the safety and effectiveness of the vaccine to ensure ongoing protection of the EU public. Our work will always be guided by the scientific evidence and our commitment to safeguard the health of EU citizens”